$400m Heptares Acquisition To Drive Sosei’s R&D
This article was originally published in PharmAsia News
Executive Summary
Sosei is to pay up to $400 million to acquire the UK structure-based drug design specialist Heptares Therapeutics in a move that the Japanese firm hopes will bring fresh fuel to its R&D engine, complementing its existing nanotech and peptide technologies.